Advertisement
Advertisement
EPRX
Eupraxia Pharmaceuticals Inc. Common Stock
8.79
USDSponsored
0.00
0.00%
Feb 05, 10:09 UTC -5
Open
EPRX Earnings Reports
Positive Surprise Ratio
EPRX beat 9 of 15 last estimates.
60%
Next Report
Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q3 25 (Revenue/ EPS)
--
/--
Implied change from Q-- -- (Revenue/ EPS)
--
/--
Eupraxia Pharmaceuticals Inc. Common Stock earnings per share and revenue
On Nov 04, 2025, EPRX reported earnings of -0.26 USD per share (EPS) for Q3 25, missing the estimate of -0.22 USD, resulting in a -18.61% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +4.04% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
Amgen Inc
Report Date
Feb 03, 2026 For Q4 25
Estimate
$4.82
Actual
$5.29
Surprise
+9.56%
Bristol-Myers Squibb Co.
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.12
Actual
$1.26
Surprise
+11.88%
GSK plc - ADR
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.23
Actual
$0.49
Surprise
+111.36%
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.82
Actual
$11.44
Surprise
+5.65%
QIAGEN N.V.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.64
Actual
$0.62
Surprise
-3.32%
Bio-Techne Corp.
Report Date
Feb 04, 2026 For Q2 26
Estimate
$0.44
Actual
$0.46
Surprise
+3.95%
Twist Bioscience Corporation Common Stock
Report Date
Feb 02, 2026 For Q1 26
Estimate
-$0.43
Actual
-$0.50
Surprise
-14.00%
Mesoblast Limited - ADR
Report Date
Jan 29, 2026 For Q1 26
Estimate
-$0.06
Actual
-$0.07
Surprise
-5.90%
AYTU BioPharma, Inc. Common Stock
Report Date
Feb 03, 2026 For Q2 26
Estimate
-$0.61
Actual
-$1.05
Surprise
-71.57%
FAQ
What were Eupraxia Pharmaceuticals Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Eupraxia Pharmaceuticals Inc. Common Stock reported EPS of -$0.26, missing estimates by -18.61%, and revenue of $0.00, 0% as expectations.
How did the market react to Eupraxia Pharmaceuticals Inc. Common Stock's Q3 2025 earnings?
The stock price moved up 4.04%, changed from $5.45 before the earnings release to $5.67 the day after.
When is Eupraxia Pharmaceuticals Inc. Common Stock expected to report next?
The next earning report is scheduled for --.
What are the forecasts for Eupraxia Pharmaceuticals Inc. Common Stock's next earnings report?
Based on --
analysts, Eupraxia Pharmaceuticals Inc. Common Stock is expected to report EPS of -- and revenue of -- for Q-- --.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement